Sanofi Q4 earnings hit by weak dollar, generic competition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sanofi (SNY) shares slide following Q4 revenue miss
February 1, 2024 8:42 AM ESTSanofi (NASDAQ: SNY) shares are down premarket following its fourth-quarter earnings release, which saw revenue come in below consensus expectations.
The pharmaceutical and healthcare company reported Q4 EPS of EUR1.66, EUR0.74 better than the analyst estimate of EUR0.92. Revenue for the quarter was EUR10.92 billion versus the consensus estimate of EUR12.65 billion.
Q4 sales rose 9.3% year-on-year, with vaccine sales up... More
